Importer Listing GN-07 and Distributor Listing GN-09: Whether to Apply

1. Key takeaways

Importer listing and distributor listing are voluntary arrangements under the Medical Device Administrative Control System (MDACS). They are governed by GN-07, Guidance Notes on Listing of Importers of Medical Devices, and GN-09, Guidance Notes on Listing of Distributors of Medical Devices, both of which were updated on 1 September 2026. Because neither is compulsory, the decision cannot be framed as a question of legal obligation. It should be framed as 2 questions instead: does your role include bringing devices into Hong Kong, China or distributing them within Hong Kong, China, and will your customers verify the public lists before they buy.

Where both answers are yes, the return on listing clearly exceeds the cost. The listing places the entity on a register that procurement officers, hospital buyers and compliance teams actually consult, and it converts an unverifiable claim about local presence into a checkable entry. That is a commercial asset, not a regulatory formality.

The two listings are also separate from device listing. A company can hold a valid importer listing while the products it handles are unlisted, and a manufacturer can hold device listings while its local distributor appears on no register at all. Tender files normally require both, which is why the two tracks have to be planned together even though they are applied for separately.

2. Legal basis

GN-07 addresses the listing of importers and GN-09 the listing of distributors, and both were reissued in updated form on 1 September 2026. GN-07 provides at clause 7.5 for additional conditions, and GN-09 provides at clause 4.9 for the same mechanism. The operating requirements that follow a successful application sit in COP-04, Code of Practice for Listed Importers of Medical Devices, and COP-05, Code of Practice for Listed Distributors of Medical Devices, both updated on the same date. MDD announced the package through its news page on medical device administrative control system developments on 1 September 2026.

The additional conditions mechanism is the provision that changes the character of a listing. In form it allows MDD to attach conditions to an approval; in effect it converts a single approval decision into an ongoing relationship in which the holder must demonstrate compliance with conditions that may be specific to that holder. Reading only the eligibility criteria and ignoring clause 7.5 or clause 4.9 leaves the applicant unprepared for the terms on which the listing is actually granted.

3. Expert insights

The 1 September 2026 revision rolled the additional conditions mechanism across the guidance set. 5 guidance notes updated in the same batch, GN-01, GN-04, GN-07, GN-08 and GN-09, each contain a corresponding additional conditions clause, and GN-07 clause 7.5, GN-09 clause 4.9 and GN-01 clause 5.10 are structurally consistent. The implication is direct: the era in which a listing was a one-off approval has ended. A listing is now a status that can carry holder-specific obligations, and those obligations have to be operated, evidenced and renewed.

The public lists are the key variable in the decision. The MDD website publishes 6 public lists: medical devices, local responsible persons, conformity assessment bodies, importers, distributors and local manufacturers. Buyers can search them directly. Under Phase C procurement, a trader that does not appear on the relevant list is at a disadvantage in a tender, a practical estimate based on how procurement verification works rather than on a published rule. The visibility effect, not the legal effect, is what most companies are actually buying.

Overlapping roles call for a single application structure. Where a group performs both import and distribution functions, the entity structure should be settled before deciding whether to file 1 application or 2. Filing twice for one operating reality adds continuing compliance cost, because each listing carries its own code of practice obligations, its own conditions and its own record set. The right question is which entity performs which function, not how many certificates look safer.

Trader listing and device listing are independent tracks. Completing an importer listing does not mean the products that importer handles are listed, and the reverse is equally true. Tender documentation usually requires evidence of both, and a bid that supplies one while implying the other creates a credibility problem that is difficult to repair after the fact. The two tracks also have different owners inside a company, which is why they drift apart.

Voluntary does not mean inconsequential. Because listing is voluntary, a company can trade without it. What it cannot do is present itself as verified. When a hospital group or a licensed private facility asks for evidence of local regulatory standing, the absence of a listing is an answer in itself, and it is read as a risk indicator rather than as a neutral choice.

4. Practical recommendations

• Draw the supply chain role map first. Set out how each group entity sits across the three roles of importer, distributor and LRP, then decide the application combination on that map rather than on convenience.
• Work backwards from customer requirements. Where the main customers are the Department of Health, the Hospital Authority or licensed private healthcare facilities, prioritise trader listing, because those customers verify standing before they contract.
• Put additional conditions into the compliance register. After approval, record each condition and its performance deadline individually, with an owner and a review date, rather than filing the approval letter and moving on.
• Self-check the public list entry quarterly. Confirm that the company name, address and scope shown on the MDD public list are accurate and current, since buyers read that entry as the authoritative statement.
• Confirm the version in force. Verify that the working copies of GN-07 and GN-09 are the versions updated on 1 September 2026, and retire earlier copies from internal folders.

5. Verification checklist

• □ Importer, distributor and LRP roles mapped for each group entity.
• □ Decision recorded on whether importer listing, distributor listing or both are required.
• □ Additional conditions in the approval letter read, registered and assigned performance deadlines.
• □ Company information checked against the MDD public list.
• □ GN-07 and GN-09 confirmed as the versions updated on 1 September 2026.
• □ Verification requirements of main customers assessed before the application decision.
• □ COP-04 and COP-05 obligations reflected in standard operating procedures.

Regulatory information verified as at 29 October 2026 against the official sources listed under legal basis; where those sources are updated, the latest published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team coordinates local responsible persons, import and wholesale dealer licensing, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com